Jeanne Stuckey
Overview
Explore the profile of Jeanne Stuckey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardenas E, ORourke R, Menon A, Vega-Hernandez G, Meagher J, Stuckey J, et al.
ACS Med Chem Lett
. 2025 Jan;
16(1):96-100.
PMID: 39811141
Dysregulation of translation is a hallmark of cancer that enables rapid changes in cellular protein production to shape oncogenic phenotypes. Translation initiation is governed by the mGpppX cap-binding protein eukaryotic...
2.
Cardenas E, ORourke R, Menon A, Vega-Hernandez G, Meagher J, Stuckey J, et al.
bioRxiv
. 2024 Oct;
PMID: 39386734
Melanoma is the deadliest form of skin cancer with a 5-year survival rate of less than 20%. While significant strides have been made in the field of kinase-targeted and immune-based...
3.
Cardenas E, ORourke R, Menon A, Meagher J, Stuckey J, Garner A
J Med Chem
. 2023 Jul;
66(15):10734-10745.
PMID: 37471629
Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the mGpppX-cap at the 5' terminus of coding mRNAs to initiate cap-dependent translation. While all cells require...
4.
Cardenas E, ORourke R, Menon A, Meagher J, Stuckey J, Garner A
bioRxiv
. 2023 Jun;
PMID: 37292917
Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the m GpppX-cap at the 5' terminus of coding mRNAs to initiate cap-dependent translation. While all cells...
5.
Hu J, Hu B, Xu F, Wang M, Qin C, McEachern D, et al.
J Med Chem
. 2023 Jun;
66(12):8222-8237.
PMID: 37289649
Starting from a nonselective bromodomain and extraterminal (BET) inhibitor and a cereblon ligand, we have used precise conformational control for the development of two potent and highly selective BRD4 degraders,...
6.
Zhang M, Aguilar A, Xu S, Huang L, Chinnaswamy K, Sleger T, et al.
J Med Chem
. 2021 Jul;
64(14):10333-10349.
PMID: 34196551
Targeting the menin-MLL protein-protein interaction is being pursued as a new therapeutic strategy for the treatment of acute leukemia carrying MLL-rearrangements (MLLr leukemia). Herein, we report M-1121, a covalent and...
7.
Chen J, Zhou Y, Dong X, Liu L, Bai L, McEachern D, et al.
J Med Chem
. 2020 Nov;
63(22):13994-14016.
PMID: 33185101
We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 has an IC...
8.
Rej R, Wang C, Lu J, Wang M, Petrunak E, Zawacki K, et al.
J Med Chem
. 2020 Jun;
63(13):7252-7267.
PMID: 32580550
Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy. Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor. EEDi-5285...
9.
Xu S, Aguilar A, Huang L, Xu T, Zheng K, McEachern D, et al.
J Med Chem
. 2020 Apr;
63(9):4997-5010.
PMID: 32338903
Targeting the menin-MLL protein-protein interaction is a new therapeutic strategy for the treatment of acute leukemia carrying MLL fusion (MLL leukemia). We describe herein the structure-based optimization of a class...
10.
Han X, Zhao L, Xiang W, Qin C, Miao B, Xu T, et al.
J Med Chem
. 2019 Dec;
62(24):11218-11231.
PMID: 31804827
Androgen receptor (AR) is a validated therapeutic target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). We report herein our design, synthesis, and biological characterization of highly potent small-molecule...